Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development.

Autor: França CT; Division of Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, Australia.; Department of Medical Biology, University of Melbourne, Parkville, Australia., White MT; Division of Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, Australia.; MRC Center for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom., He WQ; Department of Medical Biology, University of Melbourne, Parkville, Australia.; Division of Infection and Immunity, Walter and Eliza Hall Institute, Parkville, Australia., Hostetler JB; Malaria Programme, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States., Brewster J; Division of Infection and Immunity, Walter and Eliza Hall Institute, Parkville, Australia., Frato G; Center for Global Health and Diseases, Case Western Reserve University, Cleveland, United States., Malhotra I; Center for Global Health and Diseases, Case Western Reserve University, Cleveland, United States., Gruszczyk J; Division of Infection and Immunity, Walter and Eliza Hall Institute, Parkville, Australia., Huon C; Malaria Parasite Biology and Vaccines Unit, Institut Pasteur, Paris, France., Lin E; Malaria Immuno-Epidemiology Unit, PNG Institute of Medical Research, Yagaum, Papua New Guinea., Kiniboro B; Malaria Immuno-Epidemiology Unit, PNG Institute of Medical Research, Yagaum, Papua New Guinea., Yadava A; Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, United States., Siba P; Malaria Immuno-Epidemiology Unit, PNG Institute of Medical Research, Yagaum, Papua New Guinea., Galinski MR; International Center for Malaria Research, Education, and Development, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, United States.; Infectious Diseases Division, Department of Medicine, Emory University, Atlanta, United States., Healer J; Department of Medical Biology, University of Melbourne, Parkville, Australia.; Division of Infection and Immunity, Walter and Eliza Hall Institute, Parkville, Australia., Chitnis C; Malaria Parasite Biology and Vaccines Unit, Institut Pasteur, Paris, France.; International Centre for Genetic Engineering and Biotechnology, New Delhi, India., Cowman AF; Department of Medical Biology, University of Melbourne, Parkville, Australia.; Division of Infection and Immunity, Walter and Eliza Hall Institute, Parkville, Australia., Takashima E; Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, United States., Tsuboi T; Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan., Tham WH; Department of Medical Biology, University of Melbourne, Parkville, Australia.; Division of Infection and Immunity, Walter and Eliza Hall Institute, Parkville, Australia., Fairhurst RM; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, United States., Rayner JC; Malaria Programme, Wellcome Trust Sanger Institute, Hinxton, United Kingdom., King CL; Center for Global Health and Diseases, Case Western Reserve University, Cleveland, United States., Mueller I; Division of Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, Australia.; Department of Medical Biology, University of Melbourne, Parkville, Australia.; Malaria Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France.; Barcelona Institute of Global Health, Barcelona, Spain.
Jazyk: angličtina
Zdroj: ELife [Elife] 2017 Sep 26; Vol. 6. Date of Electronic Publication: 2017 Sep 26.
DOI: 10.7554/eLife.28673
Abstrakt: The study of antigenic targets of naturally-acquired immunity is essential to identify and prioritize antigens for further functional characterization. We measured total IgG antibodies to 38 P. vivax antigens, investigating their relationship with prospective risk of malaria in a cohort of 1-3 years old Papua New Guinean children. Using simulated annealing algorithms, the potential protective efficacy of antibodies to multiple antigen-combinations, and the antibody thresholds associated with protection were investigated for the first time. High antibody levels to multiple known and newly identified proteins were strongly associated with protection (IRR 0.44-0.74, p<0.001-0.041). Among five-antigen combinations with the strongest protective effect (>90%), EBP, DBPII, RBP1a, CyRPA, and PVX_081550 were most frequently identified; several of them requiring very low antibody levels to show a protective association. These data identify individual antigens that should be prioritized for further functional testing and establish a clear path to testing a multicomponent P. vivax vaccine.
Databáze: MEDLINE